brexucabtagene autoleucel
FDA Eliminates REMS for 6 CAR T-Cell Immunotherapies
The FDA announced it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for six currently approved ...
JULY 8, 2025
Tecartus Approved as First CAR T-Cell Therapy for Mantle Cell Lymphoma
The FDA approved the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus, Kite) for ...
JULY 28, 2020
Load more